DWP
REGN icon

Daymark Wealth Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

Daymark Wealth Partners’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-943
Closed -$729K – 851
2026
Q1 		$729K Buy
943
+614
+187% +$470K 0.02% 349
2025
Q4 		$254K Buy
+329
New +$223K 0.01% 529
2025
Q2 		– Sell
-523
Closed -$332K – 570
2025
Q1 		$332K Buy
523
+180
+52% +$124K 0.01% 396
2024
Q4 		$244K Sell
343
-12
-3% -$10.1K 0.01% 449
2024
Q3 		$373K Buy
355
+60
+20% +$66.8K 0.02% 388
2024
Q2 		$310K Sell
295
-52
-15% -$50.4K 0.01% 394
2024
Q1 		$334K Hold
347
– – 0.02% 326
2023
Q4 		$305K Buy
347
+100
+40% +$82.3K 0.02% 318
2023
Q3 		$203K Buy
+247
New +$194K 0.01% 364
2023
Q2 		– Sell
-248
Closed -$204K – 385
2023
Q1 		$204K Buy
+248
New +$187K 0.03% 280

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Daymark Wealth Partners's REGN Position: Q2 2026 in Review

Daymark Wealth Partners sold out of Regeneron Pharmaceuticals (REGN) in Q2 2026, closing a stake of 943 shares — an estimated $729K sold.

Daymark Wealth Partners first reported a position in REGN in Q1 2023 and held it in 10 quarters. The position peaked at $729K in Q1 2026. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Daymark Wealth Partners reported no remaining Regeneron Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Daymark Wealth Partners sold 943 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $729K.
  • Daymark Wealth Partners first reported a position in Regeneron Pharmaceuticals in Q1 2023 and held it in 10 quarters.
  • Daymark Wealth Partners's Regeneron Pharmaceuticals position peaked at $729K in Q1 2026.
  • 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Daymark Wealth Partners's 13F filing for Q2 2026, filed 31 Jul 2026.